Loading...
Anti–CTLA-4 therapy requires an Fc domain for efficacy
Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved “checkpoint”-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate...
Saved in:
| Published in: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
National Academy of Sciences
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5899492/ https://ncbi.nlm.nih.gov/pubmed/29581255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1801524115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|